Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Use of the MyDose Coach Digital Tool for Self-titration of Insulin in Patients With Type 2 Diabetes
Scientific studies show that the introduction of digital tools led to: Significant
improvement in glycemic control, greater patient satisfaction, reduction of emotional burden,
reduction of fear of hypoglycaemia, reduction of anxiety of the regimen, significantly fewer
of additional visits to the doctor in addition to those scheduled and a reduction of
resources.
Primary Objective:
To evaluate the efficacy and safety of the MyDose Coach digital tool in patients with T2D
with basal insulin or candidates for the use of basal insulin.
Secondary Objectives:
Evaluate demographic variables and control variables (HbA1c, SMPG, FPG). Measure the units of
insulin used before and after the intervention
Status | Recruiting |
Enrollment | 300 |
Est. completion date | August 22, 2019 |
Est. primary completion date | June 22, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Have type 2 diabetes - Greater than 18 years and up to 75 years of age - Use of basal insulin once a day or candidate for basal insulin once a day based on% HbA1c according to international guidelines and doctor's criteria - HbA1c > 7% in patients aged 18 to 65 years - HbA1c > 7.5% in patients older than 65 years - Patients who use basal insulin twice a day or premix with diagnosed hypoglycemia and who are candidates for switching from therapy to a basal insulin of one application per day - Have a Smartphone - Informed consent signature Exclusion Criteria: - Refuse to participate in the study. - Age younger than 18 years old and over 75 years old. - Diabetes type 1 or gestational (other than type 2 diabetes mellitus). - Patients with the following chronic complications of diabetes: retinopathy and chronic kidney disease with a glomerular filtration rate <30 ml / min. - The MyDose Coach tool is not appropriate for the patient or the use of the application is contraindicated (in the opinion of the Researcher, for example, patients with terminal illness, patients with cognitive or neurological disorders that are detailed below, patients who live alone and they do not have support from the family, patients with carpal tunnel who are not recommended to use a mobile phone, patients with musculoskeletal injuries in their hands, etc.) - Patients who use insulin during the meal (short-acting analogue, regular human insulin or insulin premix) for more than 10 days in the last 3 months before the screening visit. - Patients with severe hypoglycemia in the last 90 days. - Hospitalization in the last 30 days (whatever the reason for hospitalization) In the last 3 months prior to the screening period: history of myocardial infarction, unstable angina, acute coronary syndrome, revascularization procedure, cerebrovascular accident requiring hospitalization. - Severe or uncontrolled congestive heart failure (functional classification III and IV of the New York Heart Association [NYHA]). - Use of systemic glucocorticoids (excluding topical application or inhaled forms) for a week or more within 90 days prior to the time of the test. - Unable to meet specific protocol requirements (for example, inability to perform blood glucose measurements, administer your own insulin dose, or consider it unlikely that you will administer the titration safely according to your physician's guidance). - Patients with cognitive disorders, dementia or any neurological disorder that affects the patient's ability to participate in the study, including the inability to understand the requirements of the study or to provide complete information about the adverse symptoms. - Pregnant or breast-feeding women or women who intend to become pregnant during the study period. |
Country | Name | City | State |
---|---|---|---|
Mexico | Clínica Nova | San Nicolás De Los Garza | Nuevo León |
Lead Sponsor | Collaborator |
---|---|
Hospital Universitario Dr. Jose E. Gonzalez | Hospital Clínica Nova |
Mexico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of patients reaching fasting SMPG target without a severe hypoglycemic episode during the 16-week on-treatment period | Percentage of patients reaching fasting SMPG (Self-Measured Plasma Glucose) target range 90-130 mg/dL (5.0-7.2 mmol/L) at Week 16 (mean of the last 4 readings recorded over the last 2 weeks) without a severe hypoglycemic episode (defined as having low blood glucose levels that requires assistance from another person to treat) during the 16-week on-treatment period | 16 weeks | |
Secondary | Mean HbA1c change from baseline | Mean Glycated hemoglobin A1c (in percentage) from baseline | 16 weeks | |
Secondary | Percentage of patients reaching HbA1c of <7.5% and <7% | Percentage of patients reaching Glycated hemoglobin A1c of <7.5% and <7% | 16 weeks | |
Secondary | Mean fasting SMPG glucose change from baseline | Mean fasting Self-Measured Plasma Glucose (mean of the last 4 readings recorded over the last 2 weeks, in mg/dl) | 16 weeks | |
Secondary | Time to reach the first fasting SMPG target | Time in weeks to reach the first fasting SMPG target range of 90-130 mg/dL (5.0-7.2 mmol/L) | 16 weeks | |
Secondary | Mean FPG glucose change from baseline | Mean fasting plasma glucose glucose change from baseline, in mg/dl | 16 weeks | |
Secondary | Percentage of patients with hypoglycemic events | Percentage of patients with hypoglycemic events (blood glucose less than 70 mg/dL) | 16 weeks | |
Secondary | Number of hypoglycemic events | Number of hypoglycemic events (blood glucose less than 70 mg/dL) | 16 weeks | |
Secondary | Percentage of patients with adverse events | Percentage of patients with adverse events (other than hypoglycemia) | 16 week | |
Secondary | Assessment of emotional well-being using WHO-5 well-being index | Assessment of emotional well-being using WHO-5 well-being index. The World Health Organisation- Five Well-Being Index (WHO-5) is a short self-reported measure of current mental wellbeing. | 16 week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |